Background
Background Symptom rating scales Symptom rating scales are now well established in schizophrenia are now well established in schizophrenia research buttheir scores are notthe same research buttheir scores are notthe same as outcome. as outcome.
Aims Aims To appraise the usefulness of
To appraise the usefulness of symptom rating scales in evaluating the symptom rating scales in evaluating the outcome of people with schizophrenia. outcome of people with schizophrenia.
Method
Method Literature on the use of the Literature on the use of the Brief Psychiatric Rating Scale (BPRS) the Brief Psychiatric Rating Scale (BPRS) the Positive and Negative Syndrome Scale Positive and Negative Syndrome Scale (PANSS) and the Clinical Global (PANSS) and the Clinical Global Impression (CGI) in schizophrenia Impression (CGI) in schizophrenia research was studied. research was studied.
Results
Results Scales were designed to make Scales were designed to make diagnoses, to categorise patients, diagnoses, to categorise patients, syndromes or both, and to demonstrate syndromes or both, and to demonstrate antipsychotic efficacy, as well as to antipsychotic efficacy, as well as to measure outcome.There is much measure outcome.There is much redundancy both between and within redundancy both between and within scales.Early work suggests limited scales.Early work suggests limited concurrent validity with external outcome concurrent validity with external outcome variables.Data are at best ordinal and variables.Data are at best ordinal and there are particular difficulties in equating there are particular difficulties in equating outcome with percentage changes in outcome with percentage changes in scores.The concept of remission, which scores.The concept of remission, which uses absolute item score thresholds with a uses absolute item score thresholds with a duration criterion, is a promising outcome duration criterion, is a promising outcome measure. measure.
Conclusions Conclusions Symptom rating scale
Symptom rating scale scores can only comprise a limited part of scores can only comprise a limited part of outcome measurement. Standardised outcome measurement. Standardised remission criteria may present advantages remission criteria may present advantages in outcome research. in outcome research.
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Outcome measures are important in schizoOutcome measures are important in schizophrenia because we need to identify phrenia because we need to identify whether outcomes are modified by the whether outcomes are modified by the medications and psychosocial interventions medications and psychosocial interventions which we offer. Leaving aside social culturwhich we offer. Leaving aside social cultural and environmental factors, before the al and environmental factors, before the antipsychotic era it is unlikely that outcome antipsychotic era it is unlikely that outcome was influenced by anything other than the was influenced by anything other than the intrinsic nature and severity of the schizointrinsic nature and severity of the schizophrenic illness. Providing basic nursing care phrenic illness. Providing basic nursing care and protection probably influenced negaand protection probably influenced negative outcomes to some extent. tive outcomes to some extent.
Outcome is not a unitary construct deOutcome is not a unitary construct defined simply by lack of symptoms: personal fined simply by lack of symptoms: personal and social function, cognition and quality and social function, cognition and quality of life must be of substantial relevance. of life must be of substantial relevance. Other aspects such as economic outcome, Other aspects such as economic outcome, although important to commissioners and although important to commissioners and providers of services, might be of limited providers of services, might be of limited consequence to clinicians and patients, consequence to clinicians and patients, who naturally focus on professional and who naturally focus on professional and consumer (satisfaction) standpoints respecconsumer (satisfaction) standpoints respectively. Hence, outcome evaluation applied tively. Hence, outcome evaluation applied to services differs from that applied to to services differs from that applied to patients. patients.
Symptom rating scales in schizophrenia Symptom rating scales in schizophrenia were not initially designed to assess the were not initially designed to assess the efficacy of antipsychotic drug treatments. efficacy of antipsychotic drug treatments. Nevertheless, they have been used in this Nevertheless, they have been used in this role more than any other. This is not role more than any other. This is not surprising as antipsychotic drugs are used surprising as antipsychotic drugs are used primarily to control patients' symptoms; primarily to control patients' symptoms; the underlying neuroscience is consistent the underlying neuroscience is consistent with this, and not with any direct therapeuwith this, and not with any direct therapeutic effects on cognition, personal and social tic effects on cognition, personal and social function, or quality of life (unless mediated function, or quality of life (unless mediated by symptom control). Although such distal by symptom control). Although such distal effects have been proposed, there are effects have been proposed, there are numerous independent variables which numerous independent variables which influence these aspects of outcome (e.g. influence these aspects of outcome (e.g. upbringing, premorbid personality and upbringing, premorbid personality and adjustment, intellect and mood, social ciradjustment, intellect and mood, social circumstances and availability of a support cumstances and availability of a support network). Furthermore, it has been pronetwork). Furthermore, it has been proposed that antipsychotic drugs, particularly posed that antipsychotic drugs, particularly conventional antipsychotics, have little conventional antipsychotics, have little effect on negative symptoms of schizoeffect on negative symptoms of schizophrenia. Negative symptoms are one of phrenia. Negative symptoms are one of the most clinically important targets, and the most clinically important targets, and overlap with cognition and function (Moroverlap with cognition and function (Mortimer & Spence, 2001) . timer & Spence, 2001 ).
SYMPTOM R ATINGS SYMPTOM R ATINGS AS OUTCOME MEASURES AS OUTCOME MEASURES
Although there is evidence that changes in Although there is evidence that changes in distinct psychopathological dimensions distinct psychopathological dimensions differentially influence broader aspects of differentially influence broader aspects of outcome (Van Os outcome (Van Os et al et al, 1996) it is now , 1996) it is now accepted that fixed factors such as duration accepted that fixed factors such as duration of untreated psychosis, gender, age of onset of untreated psychosis, gender, age of onset and family psychiatric history make a suband family psychiatric history make a substantial contribution (Murray & Van Os, stantial contribution (Murray & Van Os, 1998) . Symptom rating scales can be 1998). Symptom rating scales can be viewed as quantifying the skilled clinician's viewed as quantifying the skilled clinician's judgement of current psychopathology, and judgement of current psychopathology, and change over time. The worth of routine use change over time. The worth of routine use of such rating scales in ordinary clinical of such rating scales in ordinary clinical practice is the subject of continuing debate; practice is the subject of continuing debate; the clinician makes an initial, comprehenthe clinician makes an initial, comprehensive assessment of the patient, and reviews sive assessment of the patient, and reviews this as treatment proceeds and the final outthis as treatment proceeds and the final outcome becomes clearer. The added value of a come becomes clearer. The added value of a highly structured approach can be queshighly structured approach can be questioned in a clinical review of an individual tioned in a clinical review of an individual patient's progress. Most patients manifest patient's progress. Most patients manifest only a minority of the range of possible only a minority of the range of possible symptoms and generally do not develop symptoms and generally do not develop too many new symptoms during treatment. too many new symptoms during treatment. In routine practice, symptom scales are perIn routine practice, symptom scales are perhaps little more than a formalised guide to haps little more than a formalised guide to what the clinician should be doing already. what the clinician should be doing already. They have specific utility in training junior They have specific utility in training junior staff in the full range of psychopathology staff in the full range of psychopathology they are likely to encounter, and the finer they are likely to encounter, and the finer points of mental state examination. Repoints of mental state examination. Repeated scores, represented graphically, peated scores, represented graphically, may have some utility in communicating a may have some utility in communicating a patient's progress to other clinicians. In repatient's progress to other clinicians. In research, symptom rating scales in schizosearch, symptom rating scales in schizophrenia will inform the investigator what phrenia will inform the investigator what is the nature and 'volume' of symptoms exis the nature and 'volume' of symptoms experienced by the patient, and the magnitude perienced by the patient, and the magnitude of any change over time. of any change over time.
Limitations Limitations
Symptom rating scale data can never be Symptom rating scale data can never be anything more than ordinal; the overall toanything more than ordinal; the overall total of symptom item scores will often lump tal of symptom item scores will often lump together categorical data, containing symptogether categorical data, containing symptoms associated in clusters, such as the toms associated in clusters, such as the positive, negative and disorganisation synpositive, negative and disorganisation syndromes. Specific syndrome scores derived dromes. Specific syndrome scores derived from scales may have more utility than from scales may have more utility than the total score regarding the total score regarding an overall perspecan overall perspective. Current thinking includes that schizotive. Current thinking includes that schizophrenia syndromes may comprise positive phrenia syndromes may comprise positive s 7 s 7 B R I T I S H J O UR N A L O F P S YC H I AT RY B R I T I S H J O UR N A L O F P SYC HI AT RY ( 2 0 0 7 ) , 1 9 1 ( s u p p l . 5 0 ) , s 7^s1 4 . d o i : 1 0 .11 9 2 / b j p .1 9 1 . 5 0 . s 7 ( 2 0 0 7 ) , 1 9 1 ( s u p p l . 5 0 ) , s 7^s1 4 . d o i : 1 0 . 11 9 2 / b j p . 1 9 1 . 5 0 . s 7 , 2003) represents, conceivably, a step in this direction conceivably, a step in this direction although its positive, negative, depression although its positive, negative, depression and cognitive scores are rated according and cognitive scores are rated according to judgement of severity rather than from to judgement of severity rather than from items comprising these syndromes. items comprising these syndromes.
The value of symptom item or even synThe value of symptom item or even syndrome score totals drome score totals per se per se is increasingly is increasingly questioned in the determination of outcome questioned in the determination of outcome status. A more patient-centred definition of status. A more patient-centred definition of outcome, stressing personal and social outcome, stressing personal and social function, is often viewed as more practical function, is often viewed as more practical than the presence or absence of esoteric than the presence or absence of esoteric phenomena (symptoms), which may have phenomena (symptoms), which may have little bearing on subjective experience or little bearing on subjective experience or uptake of healthcare. Influential work has uptake of healthcare. Influential work has attempted to explore the meaning and conattempted to explore the meaning and consequences of delusions and hallucinations sequences of delusions and hallucinations for patients (Chadwick & Birchwood, for patients (Chadwick & Birchwood, 1995) , but scales derived from this work 1995), but scales derived from this work are not in widespread use outside the reare not in widespread use outside the research setting. Self-administered symptom search setting. Self-administered symptom scales have been developed (Hamera scales have been developed (Hamera et al et al, , 1996) but again these have not found wide 1996) but again these have not found wide usage, in contrast to the emphasis on usage, in contrast to the emphasis on patient-rated quality of life as an outcome. patient-rated quality of life as an outcome. Clinicians increasingly seek treatment outClinicians increasingly seek treatment outcomes such as degree of independent living, comes such as degree of independent living, time to discontinuation of medication, and time to discontinuation of medication, and time to relapse and rehospitalisation rather time to relapse and rehospitalisation rather than changes in symptom rating scale than changes in symptom rating scale scores (Tiihonen scores (Tiihonen et al et al, 2006) . , 2006).
Concurrent validity Concurrent validity
The question remains whether any rating The question remains whether any rating scale (or factorial components of it) demonscale (or factorial components of it) demonstrates sufficient concurrent validity to strates sufficient concurrent validity to predict these external outcome variables. predict these external outcome variables. Operational definitions of remission may Operational definitions of remission may achieve this. These consist of multiple item achieve this. (Marshall et al et al, 2000) in mind they will , 2000) in mind they will be dealt with in some detail here. be dealt with in some detail here.
Brief Psychiatric Rating Scale Brief Psychiatric Rating Scale
The Brief Psychiatric Rating Scale (BPRS; The Brief Psychiatric Rating Scale (BPRS; ) is a one-page, ) is a one-page, 16-or 18-item rating scale which was de-16-or 18-item rating scale which was developed more than 40 years ago. It assesses veloped more than 40 years ago. It assesses a range of psychotic and affective sympa range of psychotic and affective symptoms rated from both observation of the patoms rated from both observation of the patient and the patient's own report. The tient and the patient's own report. The original purpose of the BPRS was the rapid original purpose of the BPRS was the rapid evaluation of clinical change irrespective of evaluation of clinical change irrespective of origin (e.g. natural remission or treatment origin (e.g. natural remission or treatment response) in the broad range of psychiatric response) in the broad range of psychiatric patients, not just those with schizophrenia. patients, not just those with schizophrenia. It was not, therefore, specifically designed It was not, therefore, specifically designed as an outcome measure; the authors hoped as an outcome measure; the authors hoped that the scale would develop into a diagnosthat the scale would develop into a diagnostic instrument, which they considered of tic instrument, which they considered of greater long-term value than detecting greater long-term value than detecting change. Standard definitions of outcome change. Standard definitions of outcome were developed later, e.g. 'consumer outwere developed later, e.g. 'consumer outcome is the effect on a patient's health come is the effect on a patient's health status attributable to an intervention by a status attributable to an intervention by a health professional or health service' health professional or health service' (Andrews (Andrews et al et al, 1994) . Even so, the authors , 1994). Even so, the authors later stated that the BPRS was designed to later stated that the BPRS was designed to fill a special need in clinical psychopharmafill a special need in clinical psychopharmacology research, at the inception of the cology research, at the inception of the Early Clinical Drug Evaluation Units of Early Clinical Drug Evaluation Units of the National Institute of Mental Health in the National Institute of Mental Health in the USA . the USA .
Extent of use and adaptation Extent of use and adaptation
The BPRS has perhaps been used more exThe BPRS has perhaps been used more extensively than any other symptom rating tensively than any other symptom rating scale, in many diagnostic groups and for a scale, in many diagnostic groups and for a wide range of purposes. It is highly sensitive wide range of purposes. It is highly sensitive to change, and excellent interrater reliabilto change, and excellent interrater reliability can be achieved with training and a ity can be achieved with training and a standard interview procedure (Overall & standard interview procedure (Overall & Rhoades, 1982) . As well as the evaluation . As well as the evaluation of efficacy of several classes of psychotropic of efficacy of several classes of psychotropic medication (Hedlund & Vieweg, 1980; medication (Hedlund & Vieweg, 1980; Perry Overall & Rhoades 1982; Perry et al et al, , 1997; Hamilton 1997; Hamilton et al et al, 1998) , the BPRS , 1998), the BPRS has been used extensively to compare diaghas been used extensively to compare diagnostic concepts internationally and in epinostic concepts internationally and in epidemiological studies (Delmonte demiological studies (Delmonte et al et al, , 1970; Engelsmann & Formankova, 1967; 1970; Engelsmann & Formankova, 1967; Engelsmann Engelsmann et al et al, 1970; Overall & Beller, , 1970; . It has been translated into many lan-1984). It has been translated into many languages and frequently modified for specific guages and frequently modified for specific purposes, including for use with children purposes, including for use with children Emslie (Overall & Pfefferbaum, 1982; Emslie et et al al, 1997) . It has been expanded to 24 items , 1997). It has been expanded to 24 items to make it more comprehensive in the area to make it more comprehensive in the area of psychotic and affective symptoms, with of psychotic and affective symptoms, with items on bizarre behaviour, suicidality, items on bizarre behaviour, suicidality, self-neglect, elevated mood, distractability self-neglect, elevated mood, distractability and motor hyperactivity (Ventura and motor hyperactivity (Ventura et al et al, , 2000) . The BPRS has been demonstrated 2000). The BPRS has been demonstrated as reliable for use by nursing staff, increasas reliable for use by nursing staff, increasing its utility (McGorry ing its utility (McGorry et al et al, 1988) . Most , 1988) . Most adaptations of the BPRS use one of two adaptations of the BPRS use one of two scoring versions for each item (either a 0-scoring versions for each item (either a 0-to 3-point or a 0-to 7-point scale. to 3-point or a 0-to 7-point scale.
Limitations Limitations
The factor structure of BPRS responses deThe factor structure of BPRS responses depends upon the characteristics of the papends upon the characteristics of the patient group under study, and the version tient group under study, and the version being used. The BPRS was, until the advent being used. The BPRS was, until the advent of the Positive and Negative Syndrome of the Positive and Negative Syndrome Scale (PANSS; Kay Scale (PANSS; Kay et al et al, 1987 ) which itself , 1987) which itself is partially derived from the BPRS, the most is partially derived from the BPRS, the most widely used scale in schizophrenia research. widely used scale in schizophrenia research. This reflected its broad coverage of typical This reflected its broad coverage of typical schizophrenia phenomena in the positive, schizophrenia phenomena in the positive, negative and disorganisation categories. negative and disorganisation categories. However, its coverage of the negative synHowever, its coverage of the negative syndrome has been criticised; there are only drome has been criticised; there are only three negative syndrome items, and it has three negative syndrome items, and it has been suggested that a more extensive scale been suggested that a more extensive scale is necessary for sensitivity to change (Eckert is necessary for sensitivity to change (Eckert et al et al, 1996) . , 1996). The authors themselves were dismissive The authors themselves were dismissive of the use of their scale to determine difof the use of their scale to determine differences between specific symptoms or ferences between specific symptoms or s 8 s 8
syndromes during treatment, stating that syndromes during treatment, stating that 'Although psychiatric symptomatology is 'Although psychiatric symptomatology is multidimensional, the difference between multidimensional, the difference between pre-treatment pathology and post-treatpre-treatment pathology and post-treatment pathology (or lack of it) can be reprement pathology (or lack of it) can be represented by a single dimension spanning the sented by a single dimension spanning the multivariate space' (Overall & Gorham, multivariate space' . Despite this, with the assistance of 1988). Despite this, with the assistance of 20 psychiatrists, they gave 13 different 20 psychiatrists, they gave 13 different weights to each item according to diagweights to each item according to diagnosis, in order to increase or reduce the nosis, in order to increase or reduce the relevance of treatment effects to the total relevance of treatment effects to the total score. For instance, the score on item 8, score. For instance, the score on item 8, 'grandiosity', would be multiplied by a 0 'grandiosity', would be multiplied by a 0 in a patient with depression and by 3 in a in a patient with depression and by 3 in a patient with paranoia. This complex and patient with paranoia. This complex and somewhat arbitrary scoring system appears somewhat arbitrary scoring system appears never to have been taken up. never to have been taken up.
Clinical Global Impression Clinical Global Impression
The CGI is not strictly a symptom rating The CGI is not strictly a symptom rating scale but is included because of its wide scale but is included because of its wide use, influence and the recent development use, influence and the recent development of forms specific to the schizophrenia synof forms specific to the schizophrenia syndromes (CGI-SCH). The original version dromes (CGI-SCH). The original version is a simple instrument which rates the overis a simple instrument which rates the overall severity of any mental disorder (Guy, all severity of any mental disorder (Guy, 1976) . This is rated entirely according to 1976). This is rated entirely according to clinical judgement in routine professional clinical judgement in routine professional practice, on a scale for the overall current practice, on a scale for the overall current severity of symptoms from 1 (healthy, not severity of symptoms from 1 (healthy, not ill) to 7 (among the most severely ill). There ill) to 7 (among the most severely ill). There is also a 7-point scale for global improveis also a 7-point scale for global improvement (usually from baseline to the current ment (usually from baseline to the current condition), rating from 1 (very much condition), rating from 1 (very much improved) to 7 (very much worse). The improved) to 7 (very much worse). The CGI has been used in several efficacy and CGI has been used in several efficacy and effectiveness studies in schizophrenia, is effectiveness studies in schizophrenia, is sensitive to change and correlates well with sensitive to change and correlates well with changes assessed with more complex scales changes assessed with more complex scales (Haro (Haro et al et al, 2003; Leucht & Engel, 2006; , 2003; Leucht & Engel, 2006 use over many more complex rating scales. The CGI has been adapted for the assessThe CGI has been adapted for the assessment of bipolar affective disorder ment of bipolar affective disorder (CGI-(CGI-BP) and schizophrenia (Spearing BP) and schizophrenia (Spearing et al et al, , 1997; Haro 1997; Haro et al et al, 2003) . The CGI-SCH , 2003). The CGI-SCH has demonstrated good reliability and has demonstrated good reliability and validity in the evaluation of severity of validity in the evaluation of severity of positive, negative, depressive and cognitive positive, negative, depressive and cognitive symptoms, and is recommended for both symptoms, and is recommended for both research and clinical practice. research and clinical practice.
Positive And Negative Syndrome Positive And Negative Syndrome Scale Scale
The PANSS (Kay The PANSS (Kay et al et al, 1987 (Kay et al et al, , 1988 (Kay et al et al, , 1989 (Kay et al et al, ) , 1987 (Kay et al et al, , 1988 (Kay et al et al, , 1989 ) originated from a growing need to reduce originated from a growing need to reduce the heterogeneity of what was known the heterogeneity of what was known about schizophrenia. Crow's (Crow, 1980) about schizophrenia. Crow's (Crow, 1980) positive-negative dichotomy presented a positive-negative dichotomy presented a promising theoretical model for explaining promising theoretical model for explaining and understanding variability in the aetiand understanding variability in the aetiology of schizophrenia, treatment and ology of schizophrenia, treatment and prognosis. However, attempts to utilise the prognosis. However, attempts to utilise the model in practice met with inconsistent model in practice met with inconsistent results (Andreasen, 1982; Andreasen & results (Andreasen, 1982; Andreasen & Olsen, 1982; Pogue-Geile & Harrow, Olsen, 1982; Pogue-Geile & Harrow, 1984; Lindenmayer 1984; Lindenmayer et al et al, 1986) , and it , 1986), and it was suggested that this might be because was suggested that this might be because of the lack of a comprehensive rating scale of the lack of a comprehensive rating scale for positive and negative symptoms that for positive and negative symptoms that was feasible, accurate, well validated, reliwas feasible, accurate, well validated, reliable, sensitive and standardised. The able, sensitive and standardised. The PANSS PANSS, therefore, was not developed to , therefore, was not developed to assess outcome assess outcome per se per se, or even the results , or even the results of treatment interventions. of treatment interventions.
Nature and scoring Nature and scoring
The PANSS is a 30-item 7-point (1-7) rating The PANSS is a 30-item 7-point (1-7) rating scale which amalgamated the 18-item BPRS scale which amalgamated the 18-item BPRS and 12 items from the Psychopathology and 12 items from the Psychopathology Rating Schedule (Singh & Kay, 1975) . Rating Schedule (Singh & Kay, 1975) . The items were precisely defined, as were The items were precisely defined, as were anchor points for the numerical rating of anchor points for the numerical rating of each item. The PANSS was divided into each item. The PANSS was divided into positive, negative and general psychopositive, negative and general psychopathology sub-scales (a 'manic' sub-scale pathology sub-scales (a 'manic' sub-scale was later derived; Lindenmayer was later derived; Lindenmayer et al et al, 2004) , 2004) and trialled on over 100 well-characterised and trialled on over 100 well-characterised patients with chronic illness. Sub-scale patients with chronic illness. Sub-scale scores were shown to be normally distribuscores were shown to be normally distributed and independent of each other; they ted and independent of each other; they were robust to the effects of mood, chroniwere robust to the effects of mood, chronicity, medication side-effects and cognition. city, medication side-effects and cognition. The PANSS was furthermore sensitive and The PANSS was furthermore sensitive and specific regarding pharmacological manipspecific regarding pharmacological manipulation of the levels of both positive and ulation of the levels of both positive and negative symptoms in patients with schizonegative symptoms in patients with schizophrenia. The validity of its sub-scales was phrenia. The validity of its sub-scales was confirmed in an exploration of a classificaconfirmed in an exploration of a classification of patients by predominant symptom tion of patients by predominant symptom class. Sub-scale scores were associated with class. Sub-scale scores were associated with a number of clinical, treatment and cognia number of clinical, treatment and cognitive variables, including premorbid adjusttive variables, including premorbid adjustment (Krauss ment (Krauss et al et al, 1998) , but not , 1998), but not outcome. One of the strengths claimed for outcome. One of the strengths claimed for the PANSS is consistency in scoring individthe PANSS is consistency in scoring individual patients over time and illness course. A ual patients over time and illness course. A potentially confusing feature of the PANSS, potentially confusing feature of the PANSS, however, is that even those without any however, is that even those without any mental ill health will score 30. In effect, this mental ill health will score 30. In effect, this means that 30 must be subtracted from the means that 30 must be subtracted from the patient's score in order to gain a meaningpatient's score in order to gain a meaningful understanding. ful understanding. . Overall these findings appear not to be sufficiently convincing as to be not to be sufficiently convincing as to be of clinical use, and PANSS scores have genof clinical use, and PANSS scores have generally not been used as proxy variables. For erally not been used as proxy variables. For example, when PANSS 'cognitive' items example, when PANSS 'cognitive' items were used to predict global cognitive funcwere used to predict global cognitive function 66% of the variance was unexplained, tion 66% of the variance was unexplained, suggesting that the PANSS lacked sensitivsuggesting that the PANSS lacked sensitivity and specificity in this regard (Good ity and specificity in this regard (Good et et al al, 2004) . This approach appears not to , 2004) . This approach appears not to have generated further research hypotheses. have generated further research hypotheses.
Correlations and factors Correlations and factors
Factorial validity (the nature and purity Factorial validity (the nature and purity of the syndromal components of the scale) of the syndromal components of the scale) is essential to the success of investigations is essential to the success of investigations utilising sub-scale scores. There are many utilising sub-scale scores. There are many reports on the factor (syndrome) structure reports on the factor (syndrome) structure of PANSS items, with much controversy of PANSS items, with much controversy over whether data best fit a three-, four-, over whether data best fit a three-, four-, five-or even six-factor solution (Peralta & five-or even six-factor solution (Peralta & Cuesta, 1994; Lindenmayer Cuesta, 1994; Lindenmayer et al et al, 1994; , 1994 et al, 2006) . , 2006). The simplest factor solutions comprise a The simplest factor solutions comprise a syndrome made up of negative symptom syndrome made up of negative symptom items (psychomotor poverty syndrome), a items (psychomotor poverty syndrome), a syndrome made up of delusions and hallusyndrome made up of delusions and hallucinations (reality distortion syndrome) and cinations (reality distortion syndrome) and a syndrome made up of thought disorder a syndrome made up of thought disorder and inappropriate affect symptom items and inappropriate affect symptom items (disorganisation syndrome). Although sev-(disorganisation syndrome). Although several five-factor models have been proposed, eral five-factor models have been proposed, none has been validated by confirmatory none has been validated by confirmatory factor analysis (van der Gaag factor analysis (van der Gaag et al et al, , 2006 Gaag et al et al, , 2006a . This might reflect the ambiguous ). This might reflect the ambiguous definitions of some symptom items, such definitions of some symptom items, such as lack of judgement and insight, which as lack of judgement and insight, which have more than one cause in schizophrenia. have more than one cause in schizophrenia.
Another complication is that the deAnother complication is that the depression sub-scale (unlike the Calgary pression sub-scale (unlike the Calgary Depression Scale; Addington Depression Scale; Addington et al et al, 1992) , 1992) is unable to distinguish between depression, is unable to distinguish between depression, negative symptoms and extrapyramidal negative symptoms and extrapyramidal side-effects (Collins side-effects (Collins et al et al, 1996) . Negative , 1996) . Negative factor scores have been found to correlate factor scores have been found to correlate with an independent depression rating inwith an independent depression rating instrument (Montgomery Asberg Depression strument (Montgomery Å sberg Depression Rating Scale), although depression factor Rating Scale), although depression factor scores did as well (Wolthaus scores did as well (Wolthaus et al et al, 2000) . , 2000 2006 , 2006b b) . ). Only if syndromes possess concurrent Only if syndromes possess concurrent validity with other aspects of schizophrenia validity with other aspects of schizophrenia such as cognitive impairment and poor such as cognitive impairment and poor social function, and furthermore fit explasocial function, and furthermore fit explanatory data, can they represent clinical natory data, can they represent clinical reality. The implication for the rating scale reality. The implication for the rating scale is that items which load on more than one is that items which load on more than one factor must be replaced by two or more factor must be replaced by two or more items, each of which load on a single factor, items, each of which load on a single factor, which results in lengthier scales. The alterwhich results in lengthier scales. The alternative is losing data through deletion of native is losing data through deletion of such items. Poor fit such items. Poor fit suggests that correlasuggests that correlations between syndrome tions between syndrome scores and other scores and other illness variables under investigation, includillness variables under investigation, including outcome, might be unreliable. ing outcome, might be unreliable.
MEANING OF SYMPTOM MEANING OF SYMPTOM RATING SCALE SCORES R ATING SCALE SCORES
The existence of apparently rival rating The existence of apparently rival rating scales can be confusing when they purport scales can be confusing when they purport to measure the same thing. Despite the cato measure the same thing. Despite the caveats regarding factorial purity which have veats regarding factorial purity which have been repeatedly addressed in the case of the been repeatedly addressed in the case of the PANSS, there appears to be much redun-PANSS, there appears to be much redundancy both within and between rating dancy both within and between rating scales. , 1996) . The negative symptoms of the PANSS and BPRS, tive symptoms of the PANSS and BPRS, and the SANS all measure, mostly, affective and the SANS all measure, mostly, affective flattening rather than the full range of negaflattening rather than the full range of negative symptom phenomena (Welham tive symptom phenomena (Welham et al et al, , 1999) . The much shorter and quicker CGI 1999). The much shorter and quicker CGI scales were just as good as the BPRS in disscales were just as good as the BPRS in discriminating between the effects of anticriminating between the effects of antipsychotic drugs (Leucht & Engel, 2006) psychotic drugs (Leucht & Engel, 2006) despite having been criticised on semantic, despite having been criticised on semantic, logical and statistical grounds (Beneke & logical and statistical grounds (Beneke & Rasmus, 1992) . The development of the Rasmus, 1992). The development of the CGI-SCH scale suggests that investment CGI-SCH scale suggests that investment in less complex rating instruments is gatherin less complex rating instruments is gathering pace for rating severity and treatment ing pace for rating severity and treatment response in routine clinical practice (Haro response in routine clinical practice (Haro et al et al, 2003) .
, 2003).
Even in randomised placebo-controlled Even in randomised placebo-controlled trials for licensing purposes, the use of trials for licensing purposes, the use of changes in rating scale scores may lack changes in rating scale scores may lack good face validity. Many trials evaluate good face validity. Many trials evaluate clinical response as a percentage change in clinical response as a percentage change in scores over the treatment period. Equating scores over the treatment period. Equating a 20% improvement in symptoms with a 20% improvement in symptoms with response follows the study of Kane response follows the study of Kane et al et al (1988) which compared clozapine and (1988) which compared clozapine and chlorpromazine in treatment-resistant chlorpromazine in treatment-resistant patients with severe illness. This relatively patients with severe illness. This relatively low percentage reflects the fact that in low percentage reflects the fact that in patients with severe illness even a fairly patients with severe illness even a fairly small attenuation of symptoms might be small attenuation of symptoms might be clinically valuable. The 20% definition of clinically valuable. The 20% definition of response might not, however, be generalresponse might not, however, be generalisable to the majority of acute trials with isable to the majority of acute trials with non-resistant patients. Relying on percennon-resistant patients. Relying on percentage point change to indicate recovery tage point change to indicate recovery ignores the importance of baseline levels. ignores the importance of baseline levels. A 20% reduction of a PANSS score of A 20% reduction of a PANSS score of 100 is double a 20% reduction of a PANSS 100 is double a 20% reduction of a PANSS score of 50, yet both might be recorded as a score of 50, yet both might be recorded as a 'clinical response'. The patient with a base-'clinical response'. The patient with a baseline PANSS score of 100 would, although line PANSS score of 100 would, although fulfilling criteria for response with a score fulfilling criteria for response with a score of 80, remain severely ill, (albeit noticeably of 80, remain severely ill, (albeit noticeably less so), whereas the patient with a baseline less so), whereas the patient with a baseline score of 50 would remain mildly ill with score of 50 would remain mildly ill with a score of 40 and perhaps not even be a score of 40 and perhaps not even be noticeably different. noticeably different. They used an equating procedure terms. They used an equating procedure to anchor BPRS scores to CGI categories to anchor BPRS scores to CGI categories (both severity and improvement) across (both severity and improvement) across seven drug trials which used both scales in seven drug trials which used both scales in patients with acute schizophrenia. Clinicianpatients with acute schizophrenia. Clinicianrated 'minimal improvement' on the CGI rated 'minimal improvement' on the CGI equated to a 30% improvement on the equated to a 30% improvement on the BPRS (substantially greater than the gener-BPRS (substantially greater than the generally accepted standard for response). 'Much ally accepted standard for response). 'Much improvement' after 4 weeks of treatment improvement' after 4 weeks of treatment equated to a fall in the BPRS score of equated to a fall in the BPRS score of almost 58% (Table 1 ). In addition they almost 58% (Table 1 ). In addition they found that clinicians used only a small part found that clinicians used only a small part of the BPRS score range of 18-126: paof the BPRS score range of 18-126: patients with minimum illness on the CGI tients with minimum illness on the CGI scored 31, those with moderate illnesss scored 31, those with moderate illnesss scored 41 and those with severe illness 53. scored 41 and those with severe illness 53. This is probably because patients are only This is probably because patients are only assessed on a minority of the items and assessed on a minority of the items and upon most they are scored zero. upon most they are scored zero.
Concurrent validity Concurrent validity
Using the same approach with the Using the same approach with the PANSS (Leucht PANSS (Leucht et al et al, 2005 , 2005b b) they found ) they found that 'mildly ill', 'moderately ill', 'markedly that 'mildly ill', 'moderately ill', 'markedly ill' and 'severely ill' according to the CGI ill' and 'severely ill' according to the CGI equated to total PANSS scores of 58, 75, equated to total PANSS scores of 58, 75, 95 and 116 respectively ( Table 2) . At 6 95 and 116 respectively ( Table 2) . At 6 weeks, to achieve CGI ratings of 'minimally weeks, to achieve CGI ratings of 'minimally improved' and 'much improved' the PANSS improved' and 'much improved' the PANSS decrements were 28% and 53%. The decrements were 28% and 53%. The authors suggested that response ought authors suggested that response ought to be defined as a 50% improvement to be defined as a 50% improvement in PANSS score, although in treatmentin PANSS score, although in treatmentresistant groups a decrement of 25% might resistant groups a decrement of 25% might suffice. suffice.
A later study (Leucht A later study (Leucht et al et al, 2006 (Leucht et al et al, ) com-, 2006 compared the PANSS and BPRS with each other pared the PANSS and BPRS with each other and with the CGI and replicated the findand with the CGI and replicated the findings overall, emphasising that smaller absoings overall, emphasising that smaller absolute score reductions equated to perception lute score reductions equated to perception of improvement in patients with severe of improvement in patients with severe illness compared with those with mild illness compared with those with mild illness (Table 3) . For a reduction of 1 point illness (Table 3) . For a reduction of 1 point on the CGI Severity of Illness scale there on the CGI Severity of Illness scale there were decreases of 15 and 10 on the PANSS were decreases of 15 and 10 on the PANSS and BPRS respectively. and BPRS respectively.
A similar study (Cramer A similar study (Cramer et al et al, 2001) , 2001) found that clinician-rated 'improved' and found that clinician-rated 'improved' and 'much better' patients had PANSS scores 'much better' patients had PANSS scores lowered by 21 and 45% respectively. Quallowered by 21 and 45% respectively. Quality of life scores were also increased by ity of life scores were also increased by similar degrees (26 and 50%). This is consimilar degrees (26 and 50%). This is consistent with the Leucht sistent with the Leucht et al et al (2006) (Andreasen et al et al, 2005) . , 2005). Taking precedents in physical medicine Taking precedents in physical medicine and affective disorder, remission should be and affective disorder, remission should be defined as low or mild symptom levels defined as low or mild symptom levels (which by definition do not influence (which by definition do not influence behaviour) and which should last for a behaviour) and which should last for a minimum, defined duration. Such a standminimum, defined duration. Such a standardised definition, unlike several previous ardised definition, unlike several previous published definitions, could be applied published definitions, could be applied across treatment studies and would permit across treatment studies and would permit immediate, transparent comparison. This immediate, transparent comparison. This approach does, however, require attention approach does, however, require attention to levels of baseline severity across studies. to levels of baseline severity across studies.
The Working Group aimed to map the The Working Group aimed to map the chosen remission symptoms, which had to chosen remission symptoms, which had to be rated mild or less, onto the three best valbe rated mild or less, onto the three best validated syndromes of schizophrenia (reality idated syndromes of schizophrenia (reality distortion, disorganisation and negative distortion, disorganisation and negative symptoms) and the five DSM-IV criteria symptoms) and the five DSM-IV criteria for schizophrenia (delusions, hallucinafor schizophrenia (delusions, hallucinations, disorganised speech, disorganised or tions, disorganised speech, disorganised or catatonic behaviour, negative symptoms, catatonic behaviour, negative symptoms, American Psychiatric Association, 1994). American Psychiatric Association, 1994). They picked appropriate items from the They picked appropriate items from the BPRS, the PANSS the SAPS and the SANS BPRS, the PANSS the SAPS and the SANS (Table 4) . (Table 4) .
The BPRS, with limited coverage of The BPRS, with limited coverage of negative symptoms, was perhaps less useful negative symptoms, was perhaps less useful in determining remission. The Working in determining remission. The Working Group set 6 months as the minimum duraGroup set 6 months as the minimum duration of symptoms remaining mild for the tion of symptoms remaining mild for the patient to qualify for remitted status. patient to qualify for remitted status.
Use of remission criteria Use of remission criteria
Remission is already being used in attempts Remission is already being used in attempts to test efficacy of drugs in 'head to head' to test efficacy of drugs in 'head to head' comparisons by re-analysing existing data comparisons by re-analysing existing data (Sethuraman (Sethuraman et al et al, 2005) . A study of stable , 2005). A study of stable patients using PANSS-based remission cripatients using PANSS-based remission criteria demonstrated that nearly 70% were teria demonstrated that nearly 70% were not in remission; 20% achieved remission not in remission; 20% achieved remission when switched to depot treatment and when switched to depot treatment and 85% of those already in remission 85% of those already in remission remained so a year later on depot (Lasser remained so a year later on depot (Lasser et al et al, 2005) . Application of the criteria to , 2005). Application of the criteria to data from other published studies produced data from other published studies produced similar findings (Gharabawi similar findings (Gharabawi et al et al, 2005; , 2005; Kissling Kissling et al et al, 2005) . In all studies , 2005). In all studies remission was associated with PANSS total remission was associated with PANSS total and subtotal scores, CGI-SCH scores, funcand subtotal scores, CGI-SCH scores, functioning and quality of life. Moreover, an tioning and quality of life. Moreover, an analysis of six clinical trials comparing analysis of six clinical trials comparing two definitions, one PANSS based and the two definitions, one PANSS based and the other BPRS/CGI based, found that achieveother BPRS/CGI based, found that achievement of remission using either definition ment of remission using either definition was associated with better quality of life was associated with better quality of life (Dunayevich (Dunayevich et al et al, 2006) . This was particu-, 2006). This was particularly so if remission was sustained. Neverlarly so if remission was sustained. Nevertheless, total BPRS change score still theless, total BPRS change score still contributed the greatest part of the variance contributed the greatest part of the variance in quality of life. in quality of life. Two reviews of the Working Group reTwo reviews of the Working Group remission criteria (Nasrallah, 2006; Van Os mission criteria (Nasrallah, 2006; Van Os et al et al, 2006) proposed that the definition , 2006) proposed that the definition was conceptually viable and feasible in was conceptually viable and feasible in both clinical trials and clinical practice. both clinical trials and clinical practice. Both reviews considered that the use of Both reviews considered that the use of remission criteria would raise clinical remission criteria would raise clinical expectations and drive clinical services to expectations and drive clinical services to achieve and document better outcomes. In achieve and document better outcomes. In clinical trials, the concept should improve clinical trials, the concept should improve the quality of methodology and data the quality of methodology and data reporting, while extending its relevance to reporting, while extending its relevance to cognition and functional outcomes in cognition and functional outcomes in patients. The advantages of remission patients. The advantages of remission derive from adding duration to absolute derive from adding duration to absolute symptom score thresholds, and avoiding symptom score thresholds, and avoiding percentage change scores (a hitherto percentage change scores (a hitherto dubious benchmark). dubious benchmark).
CONCLUSIONS CONCLUSIONS
Symptom rating scales which have been Symptom rating scales which have been designed to diagnose patients, subdivide designed to diagnose patients, subdivide patients, define syndromes, track clinical patients, define syndromes, track clinical change or evaluate drug efficacy do not change or evaluate drug efficacy do not lend themselves easily to the assessment of lend themselves easily to the assessment of global outcome in schizophrenia. Simply global outcome in schizophrenia. Simply totalling the number of symptoms without totalling the number of symptoms without reference to the consequences of what is reference to the consequences of what is scored, is an empty exercise. Change must scored, is an empty exercise. Change must be relative to baseline conditions; there be relative to baseline conditions; there are also issues of redundancy, and a lack are also issues of redundancy, and a lack of concurrent validity with external outof concurrent validity with external outcome measures. The effort expended invescome measures. The effort expended investigating the psychometric properties of tigating the psychometric properties of scales such as the PANSS appears to have scales such as the PANSS appears to have been matched by only limited advances in been matched by only limited advances in their utility beyond tracking change. It has their utility beyond tracking change. It has yielded little of relevance to aetiology, yielded little of relevance to aetiology, treatment or prognosis. treatment or prognosis. s11 s11 AUTHOR'S PROOF AUTHOR'S PROOF These limitations have led to interest in These limitations have led to interest in another perspective on outcome, remission. another perspective on outcome, remission. This is based on accepted practice in mediThis is based on accepted practice in medicine and other psychiatric disorders, such as cine and other psychiatric disorders, such as affective disorders, and goes beyond rating affective disorders, and goes beyond rating scale scores alone. Its utility, however, rescale scores alone. Its utility, however, remains to be seen. There are already indicamains to be seen. There are already indications that remission may be short lived in tions that remission may be short lived in many patients (Dunayevich many patients (Dunayevich et al et al, 2006) . , 2006). Until recovery can be defined accurately Until recovery can be defined accurately in schizophrenia (Leucht & Lasser, 2006) in schizophrenia (Leucht & Lasser, 2006) symptom control, remission and quantified symptom control, remission and quantified cognitive, personal and social functioning cognitive, personal and social functioning should be used together as measures of should be used together as measures of treatment outcome. This accepts that outtreatment outcome. This accepts that outcome has multiple facets, which vary in imcome has multiple facets, which vary in importance between patients. Symptom rating portance between patients. Symptom rating scales play an important role in overall scales play an important role in overall appraisal of outcome, but should not domappraisal of outcome, but should not dominate the picture, which still requires meaninate the picture, which still requires meaningful appraisals of cognition, personal and ingful appraisals of cognition, personal and social functioning. social functioning.
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